[A19-61] Pembrolizumab (non-squamous NSCLC, combination chemotherapy) - Addendum to commission A19-30

Last updated 19.09.2019

Project no.:

Commission awarded on 05.08.2019 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:


First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations

Result of dossier assessment:

PD-L1 expression < 50%: proof of major added benefit for women, indication of minor added benefit for men. PD-L1 expression ≥ 50%: hint of major added benefit for women, hint or lesser benefit for men


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations

After a methodological uncertainty has been resolved, analyses on overall survival are now usable

Federal Joint Committee (G-BA)

2019-09-19 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.